{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T18:55:39Z","timestamp":1790880939960,"version":"4.1.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,2,2]],"date-time":"2023-02-02T00:00:00Z","timestamp":1675296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,2,2]],"date-time":"2023-02-02T00:00:00Z","timestamp":1675296000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["FI 2336\/1-1"],"award-info":[{"award-number":["FI 2336\/1-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["FI 2336\/1-1"],"award-info":[{"award-number":["FI 2336\/1-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012940","name":"Universit\u00e4tsklinikum T\u00fcbingen","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100012940","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Adeno-associated viral (AAV) vector suspensions produced in either human derived HEK cells or in <jats:italic>Spodoptera frugiperda<\/jats:italic> (<jats:italic>Sf9<\/jats:italic>) insect cells differ in terms of residual host cell components as well as species-specific post-translational modifications displayed on the AAV capsid proteins. Here we analysed the impact of these differences on the immunogenic properties of the vector. We stimulated human plasmacytoid dendritic cells with various lots of HEK cell-produced and <jats:italic>Sf9<\/jats:italic> cell-produced AAV-CMV-eGFP vectors derived from different manufacturers. We found that AAV8-CMV-eGFP as well as AAV2-CMV-eGFP vectors induced lot-specific but not production platform-specific or manufacturer-specific inflammatory cytokine responses. These could be reduced or abolished by blocking toll-like receptor 9 signalling or by enzymatically reducing DNA in the vector lots using DNase. Successful HEK cell transduction by DNase-treated AAV lots and DNA analyses demonstrated that DNase did not affect the integrity of the vector but degraded extra-viral DNA. We conclude that both HEK- and <jats:italic>Sf9<\/jats:italic>-cell derived AAV preparations can contain immunogenic extra-viral DNA components which can trigger lot-specific inflammatory immune responses. This suggests that improved strategies to remove extra-viral DNA impurities may be instrumental in reducing the immunogenic properties of AAV vector preparations.<\/jats:p>","DOI":"10.1038\/s41598-023-28830-7","type":"journal-article","created":{"date-parts":[[2023,2,2]],"date-time":"2023-02-02T11:06:30Z","timestamp":1675335990000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Extra-viral DNA in adeno-associated viral vector preparations induces TLR9-dependent innate immune responses in human plasmacytoid dendritic cells"],"prefix":"10.1038","volume":"13","author":[{"given":"Kirsten","family":"Bucher","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo","family":"Rodr\u00edguez-Bocanegra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernd","family":"Wissinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Torsten","family":"Strasser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon J.","family":"Clark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas L.","family":"Birkenfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorothea","family":"Siegel-Axel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Dominik","family":"Fischer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,2,2]]},"reference":[{"key":"28830_CR1","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1038\/mt.2015.151","volume":"24","author":"T Gaj","year":"2016","unstructured":"Gaj, T., Epstein, B. E. & Schaffer, D. V. Genome engineering using Adeno-associated virus: Basic and clinical research applications. Mol. Ther. 24, 458\u2013464 (2016).","journal-title":"Mol. Ther."},{"key":"28830_CR2","doi-asserted-by":"publisher","first-page":"994","DOI":"10.3390\/ijms21030994","volume":"21","author":"M Garita-Hernandez","year":"2020","unstructured":"Garita-Hernandez, M. et al. AAV-mediated gene delivery to 3D retinal organoids derived from human induced pluripotent stem cells. Int. J. Mol. Sci. 21, 994 (2020).","journal-title":"Int. J. Mol. Sci."},{"key":"28830_CR3","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1016\/S0140-6736(17)31868-8","volume":"390","author":"S Russell","year":"2017","unstructured":"Russell, S. et al. Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: A randomised, controlled, open-label, phase 3 trial. Lancet 390, 849\u2013860 (2017).","journal-title":"Lancet"},{"key":"28830_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00109-020-02034-2","volume":"99","author":"X He","year":"2021","unstructured":"He, X., Urip, B. A., Zhang, Z., Ngan, C. C. & Feng, B. Evolving AAV-delivered therapeutics towards ultimate cures. J. Mol. Med. 99, 1\u201325. https:\/\/doi.org\/10.1007\/s00109-020-02034-2 (2021).","journal-title":"J. Mol. Med."},{"key":"28830_CR5","doi-asserted-by":"publisher","first-page":"100915","DOI":"10.1016\/j.preteyeres.2020.100915","volume":"83","author":"K Bucher","year":"2020","unstructured":"Bucher, K., Rodr\u00edguez-Bocanegra, E., Dauletbekov, D. & Fischer, M. D. Immune responses to retinal gene therapy using adeno-associated viral vectors\u2014Implications for treatment success and safety. Prog. Retin. Eye Res. 83, 100915 (2020).","journal-title":"Prog. Retin. Eye Res."},{"key":"28830_CR6","doi-asserted-by":"publisher","first-page":"2648","DOI":"10.1016\/j.ymthe.2017.08.018","volume":"25","author":"FF Reichel","year":"2017","unstructured":"Reichel, F. F. et al. AAV8 can induce innate and adaptive immune response in the primate eye. Mol. Ther. 25, 2648\u20132660 (2017).","journal-title":"Mol. Ther."},{"key":"28830_CR7","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1038\/gt.2016.31","volume":"23","author":"RF Boyd","year":"2016","unstructured":"Boyd, R. F. et al. Reduced retinal transduction and enhanced transgene-directed immunogenicity with intravitreal delivery of rAAV following posterior vitrectomy in dogs. Gene Ther. 23, 548\u2013556 (2016).","journal-title":"Gene Ther."},{"key":"28830_CR8","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1167\/tvst.10.6.15","volume":"10","author":"E Rodr\u00edguez-Bocanegra","year":"2021","unstructured":"Rodr\u00edguez-Bocanegra, E. et al. Longitudinal evaluation of hyper-reflective foci in the retina following subretinal delivery of adeno-associated virus in non-human primates. Transl. Vis. Sci. Technol. 10, 15 (2021).","journal-title":"Transl. Vis. Sci. Technol."},{"key":"28830_CR9","doi-asserted-by":"publisher","first-page":"2388","DOI":"10.1172\/JCI37607","volume":"119","author":"J Zhu","year":"2009","unstructured":"Zhu, J., Huang, X. & Yang, Y. The TLR9-MyD88 pathway is critical for adaptive immune responses to adenoassociated virus gene therapy vectors in mice. J. Clin. Investig. 119, 2388\u20132398 (2009).","journal-title":"J. Clin. Investig."},{"key":"28830_CR10","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1002\/hep.24625","volume":"55","author":"M H\u00f6sel","year":"2012","unstructured":"H\u00f6sel, M. et al. Toll-like receptor 2-mediated innate immune response in human nonparenchymal liver cells toward adeno-associated viral vectors. Hepatology 55, 287\u2013297 (2012).","journal-title":"Hepatology"},{"key":"28830_CR11","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.omtm.2020.05.018","volume":"18","author":"NG Rumachik","year":"2020","unstructured":"Rumachik, N. G. et al. Methods matter: Standard production platforms for recombinant AAV produce chemically and functionally distinct vectors. Mol. Ther. Methods Clin. Dev. 18, 98\u2013118 (2020).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"28830_CR12","doi-asserted-by":"publisher","first-page":"80","DOI":"10.3390\/biomedicines2010080","volume":"2","author":"JF Wright","year":"2014","unstructured":"Wright, J. F. Product-related impurities in clinical-grade recombinant AAV vectors: Characterization and risk assessment. Biomedicines 2, 80\u201397 (2014).","journal-title":"Biomedicines"},{"key":"28830_CR13","doi-asserted-by":"publisher","first-page":"16002","DOI":"10.1038\/mtm.2016.2","volume":"3","author":"N Cl\u00e9ment","year":"2016","unstructured":"Cl\u00e9ment, N. & Grieger, J. C. Manufacturing of recombinant adeno-associated viral vectors for clinical trials. Mol. Ther. Methods Clin. Dev. 3, 16002 (2016).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"28830_CR14","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.omtm.2018.01.002","volume":"8","author":"M Penaud-Budloo","year":"2018","unstructured":"Penaud-Budloo, M., Fran\u00e7ois, A., Cl\u00e9ment, N. & Ayuso, E. Pharmacology of recombinant adeno-associated virus production. Mol. Ther. Methods Clin. Dev. 8, 166\u2013180 (2018).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"28830_CR15","doi-asserted-by":"publisher","first-page":"e1139","DOI":"10.1002\/cti2.1139","volume":"9","author":"Y Ye","year":"2020","unstructured":"Ye, Y., Gaugler, B., Mohty, M. & Malard, F. Plasmacytoid dendritic cell biology and its role in immune-mediated diseases. Clin. Transl. Immunol. 9, e1139 (2020).","journal-title":"Clin. Transl. Immunol."},{"key":"28830_CR16","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1001\/jamaophthalmol.2019.3278","volume":"137","author":"MD Fischer","year":"2019","unstructured":"Fischer, M. D. et al. Efficacy and safety of retinal gene therapy using adeno-associated virus vector for patients with choroideremia: A randomized clinical trial. JAMA Ophthalmol. 137, 1247\u20131254 (2019).","journal-title":"JAMA Ophthalmol."},{"key":"28830_CR17","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1016\/j.ophtha.2016.03.003","volume":"123","author":"RG Weleber","year":"2016","unstructured":"Weleber, R. G. et al. Results at 2 years after gene therapy for RPE65-deficient leber congenital amaurosis and severe early-childhood\u2013onset retinal dystrophy. Ophthalmology 123, 1606\u20131620 (2016).","journal-title":"Ophthalmology"},{"key":"28830_CR18","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1089\/hum.2019.144","volume":"31","author":"AM Timmers","year":"2020","unstructured":"Timmers, A. M. et al. Ocular inflammatory response to intravitreal injection of adeno-associated virus vector: Relative contribution of genome and capsid. Hum. Gene Ther. 31, 80\u201389 (2020).","journal-title":"Hum. Gene Ther."},{"key":"28830_CR19","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/j.omtm.2020.03.007","volume":"17","author":"G Ran","year":"2020","unstructured":"Ran, G. et al. Site-directed mutagenesis improves the transduction efficiency of capsid library-derived recombinant AAV vectors. Mol. Ther. Methods Clin. Dev. 17, 545\u2013555 (2020).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"28830_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1743-422X-10-74","volume":"10","author":"BL Ellis","year":"2013","unstructured":"Ellis, B. L. et al. A survey of ex vivo\/in vitro transduction efficiency of mammalian primary cells and cell lines with nine natural adeno-associated virus (AAV1-9) and one engineered adeno-associated virus serotype. Virol. J. 10, 1\u201310 (2013).","journal-title":"Virol. J."},{"key":"28830_CR21","doi-asserted-by":"publisher","first-page":"5590","DOI":"10.4049\/jimmunol.169.10.5590","volume":"169","author":"H Yamada","year":"2002","unstructured":"Yamada, H. et al. Effect of suppressive DNA on CpG-induced immune activation. J. Immunol. 169, 5590\u20135594 (2002).","journal-title":"J. Immunol."},{"key":"28830_CR22","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.molimm.2018.01.005","volume":"94","author":"P Zhang","year":"2018","unstructured":"Zhang, P. et al. Toll-like receptor 9 antagonist suppresses humoral immunity in experimental autoimmune myasthenia gravis. Mol. Immunol. 94, 200\u2013208 (2018).","journal-title":"Mol. Immunol."},{"key":"28830_CR23","doi-asserted-by":"publisher","first-page":"eabd3438","DOI":"10.1126\/scitranslmed.abd3438","volume":"13","author":"YK Chan","year":"2021","unstructured":"Chan, Y. K. et al. Engineering adeno-associated viral vectors to evade innate immune and inflammatory responses. Sci. Transl. Med. 13, eabd3438 (2021).","journal-title":"Sci. Transl. Med."},{"key":"28830_CR24","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.phrs.2015.11.010","volume":"105","author":"D Bayik","year":"2016","unstructured":"Bayik, D., Gursel, I. & Klinman, D. M. Structure, mechanism and therapeutic utility of immunosuppressive oligonucleotides. Pharmacol. Res. 105, 216\u2013225 (2016).","journal-title":"Pharmacol. Res."},{"key":"28830_CR25","doi-asserted-by":"publisher","first-page":"S218","DOI":"10.1016\/S1525-0016(16)33355-X","volume":"24","author":"MA Brimble","year":"2016","unstructured":"Brimble, M. A. et al. 547. AAV preparations contain contamination from DNA sequences in production plasmids directly outside of the ITRs. Mol. Ther. 24, S218\u2013S219 (2016).","journal-title":"Mol. Ther."},{"key":"28830_CR26","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1038\/ni1028","volume":"5","author":"E Latz","year":"2004","unstructured":"Latz, E. et al. TLR9 signals after translocating from the ER to CpG DNA in the lysosome. Nat. Immunol. 5, 190\u2013198 (2004).","journal-title":"Nat. Immunol."},{"key":"28830_CR27","doi-asserted-by":"publisher","first-page":"5385","DOI":"10.1128\/JVI.02516-06","volume":"81","author":"P Veron","year":"2007","unstructured":"Veron, P. et al. Major subsets of human dendritic cells are efficiently transduced by self-complementary adeno-associated virus vectors 1 and 2. J. Virol. 81, 5385\u20135394 (2007).","journal-title":"J. Virol."},{"key":"28830_CR28","unstructured":"Assessment report: Glybera. https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/glybera-epar-public-assessment-report_en.pdf. Accessed 03 March 2022 (2012)"},{"key":"28830_CR29","doi-asserted-by":"publisher","first-page":"e38","DOI":"10.14440\/jbm.2016.102","volume":"3","author":"E Arden","year":"2016","unstructured":"Arden, E. & Metzger, J. Inexpensive, serotype-independent protocol for native and bioengineered recombinant adeno-associated virus purification. J. Biol. Methods 3, e38 (2016).","journal-title":"J. Biol. Methods"},{"key":"28830_CR30","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1038\/nprot.2006.207","volume":"1","author":"JC Grieger","year":"2006","unstructured":"Grieger, J. C., Choi, V. W. & Samulski, R. J. Production and characterization of adeno-associated viral vectors. Nat. Protoc. 1, 1412\u20131428 (2006).","journal-title":"Nat. Protoc."},{"key":"28830_CR31","doi-asserted-by":"publisher","first-page":"13601","DOI":"10.1038\/s41598-019-49624-w","volume":"9","author":"T Kimura","year":"2019","unstructured":"Kimura, T. et al. Production of adeno-associated virus vectors for in vitro and in vivo applications. Sci. Rep. 9, 13601 (2019).","journal-title":"Sci. Rep."},{"key":"28830_CR32","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/gt.2009.157","volume":"17","author":"E Ayuso","year":"2010","unstructured":"Ayuso, E. et al. High AAV vector purity results in serotype- and tissue-independent enhancement of transduction efficiency. Gene Ther. 17, 503\u2013510 (2010).","journal-title":"Gene Ther."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-28830-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-28830-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-28830-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,5]],"date-time":"2023-02-05T11:10:08Z","timestamp":1675595408000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-28830-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,2]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["28830"],"URL":"https:\/\/doi.org\/10.1038\/s41598-023-28830-7","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,2]]},"assertion":[{"value":"9 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 January 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.D.F. is on the advisory board of and\/or consulting and\/or receiving honoraria\/grant money\/travel support from following companies: Adelphi Values, Advent France Biotechnology, Alphasights, Arctos, Atheneum, Axiom Healthcare Strategies, Biogen, Decision Resources, Dialectica, Frontera Therapeutics, Janssen Research & Development, Navigant, Novartis, Roche, RegenxBio, Sirion, STZeyetrial. He is director of Fischer Consulting Limited and holds a patent (50%) on a gene therapy product for X-linked Retinitis Pigmentosa. S.J.C. is an inventor on patents describing the use of complement inhibitors for inflammatory disease, and is a co-founder and scientific consultant of Complement Therapeutics, which is developing complement inhibitors for therapeutic purposes including ocular disease. K.B., E.R.B, B.W., T.S., A.L.B. and D.S.-A. declare no potential conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1890"}}